US EditionPublished • loading... • Updated
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
- XORTX received a notification from Nasdaq for not meeting the minimum bid price requirement, as the closing bid price has been below US$1.00 for 30 consecutive business days.
- According to Nasdaq Rule 5550, shares must maintain a minimum bid price of US$1.00 per share, with compliance possible within 180 days.
- If XORTX's shares close at or above US$1.00 for 10 consecutive business days, it may regain compliance, according to Nasdaq Rule 5810.
- The notification does not affect XORTX's compliance status with the TSX Venture Exchange. XORTX plans to explore options to resolve this deficiency.
Insights by Ground AI
19 Articles
19 Articles
XORTX Therapeutics gains 180-day extension from Nasdaq to regain $1.00
XORTX Therapeutics (NASDAQ:XRTX) has announced that it has received an extension notice from the Nasdaq Stock Market, granting the company an additional 180 days to meet the exchange’s minimum bid price requirement of $1.00 per share. XORTX, which was
·United States
Read Full Article
The Record+9 Reposted by 9 other sources
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney…
·Waterloo, Canada
Read Full Article
Coverage Details
Total News Sources19
Leaning Left13Leaning Right3Center1Last UpdatedBias Distribution76% Left
Bias Distribution
- 76% of the sources lean Left
76% Left
L 76%
R 18%
Factuality
To view factuality data please Upgrade to Premium
